Comparative Pharmacology
Head-to-head clinical analysis: BENZTHIAZIDE versus HYDROMOX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZTHIAZIDE versus HYDROMOX.
BENZTHIAZIDE vs HYDROMOX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium reabsorption and increasing excretion of water, sodium, chloride, potassium, and hydrogen ions. Also causes vasodilation via direct arteriolar relaxation.
Inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and increasing water excretion.
Adults: 25-50 mg orally once daily initially, may increase to 100 mg daily in a single dose or two divided doses. Maximum dose: 100 mg/day.
50-100 mg orally once daily; may increase to 200 mg/day for severe edema.
None Documented
None Documented
Clinical Note
moderateBenzthiazide + Mecamylamine
"The risk or severity of adverse effects can be increased when Benzthiazide is combined with Mecamylamine."
Clinical Note
moderateDexketoprofen + Benzthiazide
"The risk or severity of adverse effects can be increased when Dexketoprofen is combined with Benzthiazide."
Terminal elimination half-life: 8-12 hours; clinical context: supports once-daily dosing for hypertension, but duration of action may extend beyond half-life due to tissue distribution.
Terminal elimination half-life: 6-9 hours; prolonged to 24-36 hours in renal impairment (CrCl <30 mL/min)
Renal: ~90% (60% unchanged, 30% as glucuronide conjugate); biliary/fecal: minimal (<5%).
Renal: 70% unchanged via tubular secretion; biliary/fecal: <10%
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic